The Company is quickly advancing both its Marijuana Breath Test (MBT) with key validation work established in March, and its ...

Medical Advisory Board additions support company’s growing product offerings across women’s health and family building. NEW ...

Inozyme recently featured new clinical insights and hosted an educational symposium at the Joint Congress of the European ...

Goldberg will sit down with CNBC’s Tim Seymour on Wednesday, June 4, for an exclusive conversation in the Special Events Area on the CMB exhibit floor. The discussion will dive into the fast-rising ...

Note: alfa pump® and DSR® are registered trademarks.

Ramsay Santé Group reported a consolidated revenue of €3,889m for the nine months period ending 31 March 2025, up 5.1% on a reported basis. Adjusted for changes in the consolidation scope and at ...

Internationally acclaimed neurologist and epilepsy researcher Dr. Orrin Devinsky will be honored with the Lifetime Accelerator Award during the Epilepsy Therapies & Diagnostics Development Symposium ...

ERNA-101 remains on track for IND-enabling studies in 2025, with first-in-human studies targeted for 2026.

Columbia University, the Company’s collaboration partner for pre-clinical development, granted Silo an exclusive global license to further develop, manufacture, and commercialize SPC-15 worldwide.

Expect to report topline data from the Seabreeze STAT COPD study in 1H 2026 – SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect ...

SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt ...

“I also want to thank Dale for his innumerable contributions to Outset during a critical period for the company. The experience, guidance and insights he brought to the board will have a lasting ...